|
Acquisition of King Pharmaceuticals, Inc. Narrative (Detail) (USD $)
In Millions, except Per Share data, unless otherwise specified |
3 Months Ended | 6 Months Ended | 3 Months Ended | 6 Months Ended | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jul. 03, 2011
|
Jul. 04, 2010
|
Jul. 03, 2011
|
Jul. 04, 2010
|
Jul. 03, 2011
King [Member]
|
Feb. 28, 2011
King [Member]
|
Jan. 31, 2011
King [Member]
|
Jul. 04, 2010
King [Member]
Pro Forma Consolidated Results [Member]
|
Jul. 03, 2011
King [Member]
Pro Forma Consolidated Results [Member]
|
Jul. 04, 2010
King [Member]
Pro Forma Consolidated Results [Member]
|
|||||||
| Business Acquisition [Line Items] | ||||||||||||||||
| Acquisition purchase price per share | $ 14.25 | $ 14.25 | ||||||||||||||
| Percent of outstanding shares initially acquired | 92.50% | |||||||||||||||
| Payments to acquire businesses, net of cash acquired | $ 3,169 | $ 3,169 | ||||||||||||||
| Gross contractual amount receivable | 200 | |||||||||||||||
| Elimination of intangible asset amortization | 38 | 6 | 79 | |||||||||||||
| Additional amortization of intangible assets | 43 | 86 | ||||||||||||||
| Additional depreciation expense | 9 | 3 | 17 | |||||||||||||
| Purchase accounting adjustment for estimated sales of acquisition-date inventory at fair value | 3,805 | [1] | 3,684 | [1] | 7,498 | [1] | 7,886 | [1] | 61 | (119) | 119 | |||||
| Adjustment for acquisition-related costs | $ 63 | $ (181) | $ 181 | |||||||||||||
|
||||||||||||||||